ASCO 2024 abstract movers – Merus convinces, at first
Thursday's unveiling of regular ASCO abstract yielded a few initial winners and losers.
ASCO 2024 preview – more questions for BioNTech
Eagerly awaited data with the anti-PD-L1 x 4-1BB bispecific acasunlimab raise liver toxicity concerns.
Lilly joins the folate receptor arena
Lilly’s Mablink acquisition challenges Genmab’s move for ProfoundBio.
FDA green and red lights: April 2024
A tumour-agnostic label for Enhertu leads April’s US oncology approvals.
A new menin challenger
Hutchmed starts phase 1 with a project in a field where Syndax and Kura have so far been the main players.
ProfoundBio takeout shines a light on Sutro
Genmab’s remarkably bold acquisition raises more questions about Sutro, a key FRα rival of ProfoundBio.
